6525--Radiopharmaceuticals Brand Name or Equal

Sources Sought Notice

Sources Sought Notice

Page 6 of 6

Sources Sought Notice

*= Required Field

Sources Sought Notice

Page 1 of 6

DISCLAIMER

THIS NOTICE IS FOR PLANNING PURPOSES ONLY. THE GOVERNMENT DOES NOT INTEND TO AWARD A CONTRACT ON THE BASIS OF THIS RFI OR REIMBURSE ANY COSTS ASSOCIATED WITH THE PREPARATION OF RESPONSES TO THIS RFI.

This RFI is issued solely for information and planning purposes and does not constitute a Solicitation, an Invitation for Bids, a Request for Proposal (RFP), a Request for Quotation (RFQ), or an indication the Government will contract for the items contained in this announcement. All information received in response to this RFI marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. In accordance with FAR 15.201(e), responses to this RFI are not offers and cannot be accepted by the Government to form a binding contract.

PURPOSE

The purpose of this RFI is to conduct market research to find qualified vendors and to assist Network Contracting Office (NCO) 6 in determining if a future contract effort can be competitively awarded for a Set-Aside. The applicable North American Industrial Classification System (NAICS) code assigned to this effort is 325412 Pharmaceutical Preparation Manufacturing the Small Business Size Standard of 1250 employees. If the Government determines there are qualified vendors this requirement, a solicitation will be published and posted on the Contracting Opportunities website. The Government will use this information solely to determine the appropriate acquisition strategy for this procurement.Â

INTRODUCTION

The Asheville VAMC has a requirement for a Base plus 3 Option Years for nuclear medicine services to be provided for requested radiopharmaceuticals and associated supplies within 90 minutes of receipt of requirement notification.

Period of Performance:

Base Year 10-01-2023 to 09-30-2024

Option Year #1 10-01-2024 to 09-30-2025

Option Year #2 10-01-2025 to 09-30-2026

Option Year #3 10-01-2026 to 09-30-2027

REQUIREMENTS

NOTE: The VHA Network Contracting Office 6 (NCO 6) is conducting a market survey to find qualified vendors who can provide the following item(s) for the Charles George, Asheville VA Medical Center, 1100 Tunnel Road, Asheville, NC 28805:

Manufacturer: SHERTECH Spartanburg LLC

Item #

PRODUCTS/SERVICES (inc. software, licenses, etc.): Description/Part Number*

Qty

1

99mTc Pertechnetate-(Point Flood Source), 500 uCi-3 mCi

40

2

99mTc Pertechnetate-(Linearity Source), per mCi

500

3

99mTc Pertechnetate, 0 to 25 mCiÂ

10

4

99mTc Sulfur Colloid, 0 to 8 mCiÂ

3

5

99mTc Sulfur Colloid, 15 mCiÂ

4

6

99mTc Sulfur Colloid, (filtered), 0.5-2 mCi

4

7

99mTc MAA, 0 to 5 mCiÂ

30

8

99mTc HDP, 0 to 30 mCi

1

9

99mTc MDP, 0 to 30 mCiÂ

120

10

99mTc DTPA, 0 to 20 mCiÂ

1

11

99mTc DTPA, 21 to 75 mCi

30

12

99mTc MAG 3, 0 to 10 mCiÂ

25

13

99mTc Choletec, (or Mebrofenin-generic) 0 to 10 mCiÂ

35

14

123 Iodine Diagnostic Capsule, 100 uCi

4

15

123 Iodine Diagnostic Capsule, 200 uCi

25

16

123 Iodine MIBG, 10 mCi

1

17

123 Iodine-WB-Diagnostic Capsule, 0-3 mCi

1

18

Ceretec (Tc99m Labeled) WBC, 10-30 mCI

1

19

(In111 Labeled) WBC, 0 to 1 mCi

1

20

99mTc Sestamibi, 10 mCi

900

21

99m Tc Sestamibi, 30 mCi  Â

900

22

Cobalt 57 Sheet sources-up to 20 mCi

1

23

Cobalt 57 vial sources-5 mCi

1

24

Cobalt 57 pen markers-up to 200 uCi

1

25

Cobalt 57 spot markers-up to 100 uCi

2

26

Cesium 137 vial sources-200 uCi

1

27

Cesium 137 spot sources- up to 10 uCi

4

28

WBC Setup syringe 1000-1500 units heparin in 1-2 ml, total volume 50-60 ml

6

29

Pyrophosphate, per vialÂ

5

30

RBC Tagging Kit, Ultratag per kitÂ

5

31

Sincalide, (generic Kinevac), 0-2 mcg in 50 ml bag

1

32

Sincalide (generic Kinevac), each additional mcg

1

33

Survey Meter Calibration by accredited company

6

34

Syringe Shields (Not included for PET or NM therapy RAM)

6

35

Boost

85

36

Aerovent Jr. Model# L101--805, SN 001505 / BX (Part# AV-100H)

3

37

Misc. charges for (shipping charges, emergency call back after clinic hours)

3

38

Fuel surcharges (per delivery)

285

39

Misc. charges not listed above (for any other items-add separate line item starting here)

1

40

Any additional Non-HEU cost per dose for Tc99m Products

4000

DESCRIPTION OF INFORMATION REQUESTED

Vendors with a GSA schedule shall provide the contract number of that schedule and the expiration date as well as product NAICS codes. All items should be clearly identified if they are scheduled items or open market items.

HOW TO RESPOND:

All responses shall be submitted no later than 10:00 am EDT Friday, September 22, 2023. All interested parties should respond, in writing via email to james.risbonva.gov. No telephone inquiries will be accepted. Respondents to this RFI shall provide the following information:

Company/individual name,

Address,

Point of contact with phone number

Information describing your interest,

Indicate FSS/GSA contract number or Open Market, as applicable

FSS Category you qualify for

UEI Number

Tax ID number

DUNS number

Capabilities statement

Company Socio-Economic SIZE (example large, small, SDVOSB, VOSB, WOSB etc.)

Authorized Distributor Letter

Interested firms are reminded that in accordance with FAR 4.1201(a) Prospective contractors shall complete electronic annual representations and certifications at the System for Award Management (SAM) as a part of required registration in conjunction with FAR 4.1102(a) that states, Prospective contractors shall be registered in the (SAM) database prior to award of a contract or agreement. Therefore, due to time constraints, vendors must be registered in System for Award Management (SAM) under the above NAICS code at http://www.sam.gov to be considered for an award.

Please submit responses via email in Microsoft Office format by 10:00 am (Eastern Time) 09/22/2023. Please include RFI # 36C24624Q00151 in subject title.

NOTE: Responses to this announcement will not be returned, nor will there be any ensuing discussions or debriefings of any responses. However, information obtained as a result of this announcement may be reflected in any subsequent solicitation. This announcement is Government market research purposes ONLY.